Литература. 
Сочетанность развития артериальной гипертензии и компонентов синдрома инсулинорезистентности у крыс со спонтанной гипертензией

1. Талаева Т. В., Корниенко О. В., Братусь В. В. и др. Атерогенная модификация липопротеинов крови и гиперхолестеринемия как следствия острого воспалительного процесса // Журн. АМН Украины. — 1997. — Т. 3, № 3. — С. 463−471.

2. Adiyaman A., Staessen J. A. Renin turning full circle as cardiovascular risk factor // Eur. Heart J. — 2007. — Vol. 28, № 21. — P. 2557−2558.

3. Biaggioni I. Should we target the sympathetic nervous system in the treatment of obesity-associated hypertension? // Hypertension. — 2008. — Vol. 51. — P. 168−175.

4. Bohlen H. G. Metalloproteinases damage the insulin receptor to cause insulin resistance in spontaneously hypertensive rats // Hypertension. — 2008. — Vol. 52. — P. 215−223.

5. Chobanian A. V., Bakris G. L., Black H. R. et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure // Hypertension. — 2003. — Vol. 42. — P. 1206−1252.

6. Colussi G., Catena C., Lapenna R. et al. Insulin resistance and hyperinsulinemia are related to plasma aldosterone levels in hypertensive patients // Diabetes Care. — 2007. — Vol. 30. — P. 2349−2354.

7. DeLano F. A., Schmid-Schonbein G. W. Proteinase activity and receptor cleavage. Mechanism for insulin rresistance in the spontaneously hypertensive rat // Hypertension. — 2008. — Vol. 52. — P. 415−423.

8. Dhaun N., Goddard J., Kohan D. E. et al. Role of endothelin-1 in clinical hypertension. 20 years on // Hypertension. — 2008. — Vol. 52. — P. 452−461.

9. Gaillard T., Schuster D., Osei K. Independent role of blood pressure on cardiovascular risk factors in nondiabetic, obese African-American women with family history of type 2 diabetes: Implications for metabolic syndrome components // Hypertension. — 2009. — Vol. 3. — P. 25−34.

10. Giles T. D., Berk B. C., Black H. R. et al. Expanding the definition and classification of hypertension // J. Clin. Hypertension. (Greenwich). — 2005. — Vol. 7. — P. 505−512.

11. Gress T. W., Nieto F. J., Shahar E. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus // New Engl. J. Med. — 2000. — Vol. 342. — P. 905−912.

12. Grundy S. M. Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds // J. Amer. Coll. Cardiology. — 2006. — Vol. 47. — P. 1093−1100.

13. Hajjar I., Kotchen T. A. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988;2000 // JAMA. — 2003. — Vol. 290. — P. 199−206.

14. Hu G., Sarti C., Jousilahti P. еt al. The impact of history of Hypertension and type 2 diabetes at baseline on the incidence of stroke and stroke mortality // Stroke. — 2005. — Vol. 36. — P. 2538−2543.

15. Ishikawa J., Tamura Y., Hoshide S. et al. Low-grade inflammation is a risk factor for clinical stroke events in addition to silent cerebral infarcts in Japanese older hypertensives // Stroke. — 2007. — Vol. 38. — P. 911−919.

16. Izzo R., de Simone G., Chinali M. et al. Insufficient control of blood pressure and incident diabetes // Diabetes Care. — 2009. — Vol. 32. — P. 845−850.

17. Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2004) // Hypertens. Res. — 2006. — Vol. 29 (Suppl). — P. 1−105.

18. Johnson R. J., Segal M. S., Sautin Y. et al. Potential role of sugar (fructose) in the epidemic of hypertension, obesity and the metabolic syndrome, diabetes, kidney disease, and cardiovascular disease // Amer. J. Clin. Nutr. — 2007. — Vol. 86. — P. 899−906.

19. Jordan J., Engeli S., Redon J. et al. European Society of Hypertension Working Group on Obesity: background, aims and perspectives // J. Hypertension. — 2007. — Vol. 25. — P. 897−900.

20. Juan C. C., Shen Y. W., Chien Y. et al. Insulin infusion induces endothelin-1-dependent hypertension in rats // Amer. J. Physiol. — 2004. — Vol. 287. — P. 948−954.

21. Kearney P. M., Whelton M., Reynolds K. et al. Global burden of hypertension: analysis of worldwide data // Lancet. — 2005. — Vol. 365. — P. 217−223.

22. Kokubo Y., Kamide K., Okamura T. et al. Impact of high-normal blood pressure on the risk of cardiovascular disease in a Japanese urban cohort. The Suita Study // Hypertension. — 2008. — Vol. 52. — P. 652−659.

23. Korhonen P., Aarnio P., Saaresranta T. et al. Glucose homeostasis in hypertensive subjects // Hypertension. — 2008. — Vol. 51. — P. 945−952.

24. Landsberg L. Diet, obesity and hypertension: an hypothesis involving insulin, the sympathetic nervous system, and adaptive thermogenesis // Q. J. Med. — 1986. — Vol. 61. — P. 1081−1090.

25. Luders S., Hammersen F., Kulschewski A. et al. Diagnosis of impaired glucose tolerance in hypertensive patients in daily clinical practice // Int. J. Clin. Pract. — 2005. — Vol. 59. — P. 632−638.

26. Mainous A. G., Everett C. J., Loszka H. et al. Prevention and mortality in a nationally representative cohort // Amer. J. Cardiol. — 2004. — Vol. 94. — P. 1496−1500.

27. Mancia G., De Backer G., Dominiczak A. et al. 2007 Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) // J. Hypertension. — 2007. — Vol. 25. — P. 1105−1187.

28. Modena M. G., Bonetti L., Coppi F. et al. Prognostic role of reversibile endothelial dysfunction in hypertensive postmenopausal women // J. Amer. Coll. Cardiology. — 2002. — Vol. 40. — P. 505−510.

29. Morisco C., Condorelli G., Orzi F. et al. Insulin-stimulated cardiac glucose uptake is impaired in spontaneously hypertensive rats: role of early steps of insulin signaling // J. Hypertension. — 2000. — Vol. 18. — P. 465−473.

30. Neaton J. D., Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease overall findings and differences by age for 316 099 white men // Arch. Int. Med. — 1992. — Vol. 152. — P. 56−64.

31. Nissen S. E., Tuzcu E. M., Libby P. et al. effect of antihypertensive agents on cardiovascular events in patients with coronary diseaseand normal blood pressure // JAMA. — 2004. — Vol. 292. — P. 2217−2225.

32. Raji A., Seely E. W., Bekins S. A. et al. Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients // Diabetes Care. — 2003. — Vol. 26. — P. 172−178.

33. Rodriguez-Colon S. M., Mo J., Duan Y. et al. Metabolic syndrome clusters and the risk of incident stroke: The Atherosclerosis Risk in Communities (ARIC) Study // Stroke. — 2009. — Vol. 40. — P. 200−205.

34. Rossi R., Nuzzo A., Origliani G., Modena M. G. Metabolic syndrome affects cardiovascular risk profile and response to treatment in hypertensive postmenopausal women // Hypertension. — 2008. — Vol. 52. — P. 865−872.

35. Rossi R., Turco V., Origliani G., Modena M. G. Type 2 diabetes mellitus is a risk factor for the development of hypertension in postmenopausal women // J. Hypertension. — 2006. — Vol. 24. — P. 2017;2022.

36. Sharma A. M. Is there a rationale for angiotensin blockade in the management of obesity hypertension? // Hypertension. — 2004. — Vol. 44. — P. 12−19.

37. Targonski P. V., Bonetti P. O., Pumper G. M. et al. Coronary endothelial dysfunction is associated with an increased risk of cerebrovascular events // Circulation. — 2003. — Vol. 107. — P. 2805−2809.

38. Vasan R. S., Larson M. G., Leip E. P. Impact of high-normal blood pressure on the risk of cardiovascular disease // New Engl. J. Med. — 2001. — Vol. 345. — P. 1291−1297.

39. Vijan S., Hayward R. A. Treatment of hypertension in type 2 diabetes mellitus: blood pressure goals, choice of agents, and setting priorities in diabetes care // Ann. Int. Med. — 2003. — Vol. 138 (7). — P. 593−602.

40. Wakugawa Y., Kiyohara Y., Tanizaki Y. et al. C-reactive protein and risk of first-ever ischemic and hemorrhagic stroke in a general Japanese population: the Hisayama study // Stroke. — 2006. — Vol. 37. — P. 27−32.

41. Wang D. L., Wаng B. S., Shy Y. J. et al. Mechanical strain induces monocyte chemotactic protein-1 gene expression in endothelial cells: effects of mechanical strain on monocyte adhesion to endothelial cells // Circ. Res. — 1995. — Vol. 77. — P. 294−302.

42. Weber M. Should treatment of hypertension be driven by blood pressure or total cardiovascular risk? // Renin-Angiotensin System In Cardiovascular Medicine. — 2006. — Vol. 2, № 3. — P. 16−19.

43. Wofford M. R., Anderson D. C., Brown C. A. et al. Anti-hypertensive effect of alphaand beta-adrenergic blockade in obese and lean hypertensive subjects // Amer. J. Hypertension. — 2001. — Vol. 14. — P. 694−698.

44. Yusuf S., Sleight P., Pogue J. et al. Effect of angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients // New Engl. J. Med. — 2000. — Vol. 342. — P. 145−153.